Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00241462

Purpose

The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.

Condition	Phase
Breast Cancer	Phase IV

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

Further study details as provided by AstraZeneca:

Estimated Enrollment:	150
Study Start Date:	June 2005
Estimated Study Completion Date:	December 2009

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Postmenopausal
Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment

Exclusion Criteria:

Life threatening metastases

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241462

Locations

Netherlands
Research Site
Bergen op Zoom, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Alkmaar, Netherlands
Research Site
Almelo, Netherlands
Research Site
Almere, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Apeldoorn, Netherlands
Research Site
Assen, Netherlands
Research Site
Bergen Op Zoom, Netherlands
Research Site
Capelle Aan Den Ijssel, Netherlands
Research Site
Delft, Netherlands
Research Site
Delfzijl, Netherlands
Research Site
Doetinchem, Netherlands
Research Site
Dokkum, Netherlands
Research Site
Dordrecht, Netherlands
Research Site
Ede Gld, Netherlands
Research Site
Eindhoven, Netherlands
Research Site
Geldrop, Netherlands
Research Site
Gorinchem, Netherlands
Research Site
Hardenberg, Netherlands
Research Site
Heerlen, Netherlands
Research Site
Hellevoetsluis, Netherlands
Research Site
Stadskanaal, Netherlands
Research Site
Hoogeveen, Netherlands
Research Site
Leiden, Netherlands
Research Site
Leiderdorp, Netherlands
Research Site
Leidschendam, Netherlands
Research Site
Meppel, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Oss, Netherlands
Research Site
Roermond, Netherlands
Research Site
S-Gravenhage, Netherlands
Research Site
Terneuzen, Netherlands
Research Site
Tilburg, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Vlaardingen, Netherlands
Research Site
Winschoten, Netherlands
Research Site
Winterswijk, Netherlands
Research Site
Zeist, Netherlands
Research Site
Zevenaar, Netherlands
Research Site
Zwolle, Netherlands
Research Site
Drachten, Netherlands
Research Site
Heerenveen, Netherlands
Research Site
Hilversum, Netherlands

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

AstraZeneca Netherlands Medical Director, MD

AstraZeneca

More Information

No publications provided

Study ID Numbers:	D6997-NL-001, FORUM
Study First Received:	October 18, 2005
Last Updated:	April 21, 2009
ClinicalTrials.gov Identifier:	NCT00241462 History of Changes
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by AstraZeneca:

Advanced Breast Cancer

Study placed in the following topic categories:

Skin Diseases
Fulvestrant
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Skin Diseases
Breast Neoplasms
Breast Diseases

ClinicalTrials.gov processed this record on May 07, 2009